NASDAQ:IMA
ImageneBio, Inc.
ImageneBio, Inc.'s revenue fell 77.1% in fiscal 2025 to $800,000 while operating margin fell to −6056.4%, its lowest in 6 years.Summary generated from ImageneBio, Inc.'s SEC filings. Latest annual report filed Mar 10, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$800,000
Revenue growth−77.1%
Revenue, 5-yr CAGR−38.6%
Gross marginn/a
Operating margin−6056.4%
Net margin−5668.6%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 31 | 16 | 9 | 4 | 1 |
| Operating income | −34 | −71 | −75 | −37 | −48 |
| Net income | −34 | −69 | −68 | −37 | −45 |
| Free cash flow | −62 | −76 | −80 | n/a | n/a |
Recent filings
- 4Insider transaction report
Aug 17, 2026 - 4Insider transaction report
Aug 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KDirector or officer change
Jul 23, 2026 - 8-KDirector or officer change
Jun 26, 2026 - 8-KDirector or officer change
Jun 17, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026